Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 27 January, 2012 and appeared in  Type 1 DiabetesPathologyIssue 610

New Information on Link between 'Killer Cells' and Diabetes

Our own killer T-cells in the human body which help protect us from disease may inadvertently destroy cells that produce insulin....

Advertisement

Professor Andy Sewell, an expert in human T-cells from Cardiff University's School of Medicine worked with diabetes experts from King's College London to better understand the role of T-cells in the development of Type 1 diabetes.

The team isolated a T-cell from a patient with Type 1 diabetes to view a unique molecular interaction which results in the killing of insulin-producing cells in the pancreas.

Type 1 diabetes is a result of the body's own immune system attacking and destroying the cells in the pancreas that manufacture the hormone insulin. Insulin controls blood sugar levels and a lack of insulin is fatal if untreated.

According to Professor Sewell, "The mechanism by which the body attacks its own insulin producing cells in the pancreas is not fully understood. Our findings show how killer T-cells might play an important role in autoimmune diseases like diabetes and we've secured the first ever glimpse of the mechanism by which killer T-cells can attack our own body cells to cause disease."

Co-author of the study, Professor Mark Peakman from the National Institute for Health Research (NIHR) Biomedical Research Centre at King's College London and Guy's and St. Thomas' NHS Foundation Trust said: "This first sight of how killer T-cells make contact with the cells that make insulin is very enlightening, and increases our understanding of how Type 1 diabetes may arise.

"This knowledge will be used in the future to help us predict who might get the disease and also to develop new approaches to prevent it. Our aim is to catch the disease early before too many insulin-producing cells have been damaged."

The team now hopes that by gaining a better understanding of this process it will put them in a much stronger position to devise new ways to prevent or even halt the disease.

The published study shows that the killer T-cell receptor utilizes an abnormal mode of binding in order to recognize cells producing insulin. This unusual binding is thought to allow the T-cell to survive the culling process designed to rid the body of autoreactive T-cells.

The structure of the killer T-cell receptor bound to the insulin peptide shows that the interaction is highly focused on just a small part of the molecule.

In a further study published in the Journal of Biological Chemistry the same Cardiff and King's team has shown that this focused binding mode allows this T-cell receptor to respond to over 1.3 million other peptides of different molecular shape.

This ability to bind peptides with a multitude of different shapes may provide a clue as to how autoimmune diseases are initiated. It is possible that this T-cell was raised to fight an infection via one of the other 1.3 million peptides it can recognize but then inadvertently also recognized insulin once it had been put on 'red alert' by this infection.
Nature Immunology, Jan. 2012 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 27 January, 2012 and appeared in  Type 1 DiabetesPathologyIssue 610

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

2012 Most Popular Articles:

ADA/EASD Issue New Hyperglycemia Management Guidelines
Posted April 26, 2012
Type 2 More Dangerous in Children
Posted May 03, 2012
It’s the Variety of Fruit-and-Veggie That Lower Diabetes Risk
Posted May 03, 2012
Eating Low Glycemic Index Foods at Breakfast Can Control Blood Sugar throughout the Day
Posted April 18, 2012
Ultra-Long-Acting Insulin Degludec, Two New Studies
Posted April 26, 2012
Questioning Carbohydrate Restriction in Diabetes Management
Posted May 18, 2012
Metformin May Treat a Leading Cause of Blindness
Posted May 10, 2012
A Candy Treatment that Fights Diabetes and May Replace TZD's?
Posted May 10, 2012
Metformin May Not Be the Golden Pill After All for Treating Type 2 Diabetes
Posted April 18, 2012
Doubts Over Long Term Effectiveness of Group Education for Diabetes Patients
Posted May 03, 2012

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Marilyn Porter, RD, CDE | Melissa Diane Smith | Paul Chous, M.A., OD | Philip A. Wood PhD | Sheri R. Colberg PhD | Sherri Shafer | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control
Announcement:



Search Articles On Diabetes In Control